HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Autism 'Cure' Products Spur Comment Wave On FDA's VMS Industry Oversight

Executive Summary

More than half the 73 comments posted to FDA's DSHEA modernization docket are from consumers concerned about a specific type of product, bleach-containing liquids marketed as a cure for autism.

You may also be interested in...



Bleach-Based Autism 'Cure' In FDA Crosshairs After Comments, Recent AERs

FDA says it "recently received new" AERs linked to products as it repeats a warning initially made in 2010 about dangers of products marketed as "Miracle Mineral Solution," "Miracle Mineral Supplement," "MMS," "Chlorine Dioxide (CD) Protocol," "Water Purification Solution (WPS)" and with similar brand names.

NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA

FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.

Supplement Industry's Health Linked To Improving Consumer Trust

"The difficult truth that we need to face," says Eric Pierce, New Hope Network's strategy and insights director, is that most consumers don't trust the supplement industry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel